Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding OneHarrow Initiative is Launched to Unify Branding under Harrow Patrick W. Sullivan Promoted to Serve as Harrow’s Chief Commercial Officer MELT-300 and MELT-210 Programs on Track for New Drug Application Filings Harrow’s ImprimisRx Settles Pending Regulatory Matters with the California Board of Pha ...